S36ɳÁú»á

EN
S36ɳÁú»á - ÒªÍæ¾ÍÍæÉ³Áú»á S36ɳÁú»á - ÒªÍæ¾ÍÍæÉ³Áú»á
ÐÂÎÅÖÐÐÄ
2024-12-31
Ñо¿Ö¤ÊµÒÈÏÙ°©CAR-MÁÆ·¨Çå¾²ÓÐÓÃ
ÔĶÁ¸ü¶à
2024-12-27
¡°·Ö×ÓGPS¡±Ö¸µ¼ÃâÒßϸ°ûÓÐÓá°Çå½Ë¡±ÄÔÖ×Áö
ÃÀ¹ú¼ÓÖÝ´óѧ¾É½ðɽ·ÖУ¿£¿£¿£¿£¿ÆÑ§¼Ò¿ª·¢ÁËÒ»ÖÖÁ¢ÒìµÄ¡°·Ö×ÓGPS¡±ÊÖÒÕ£¬£¬£¬Äܹ»Ö¸µ¼ÃâÒßϸ°ûÌØÒìÐԵض¨Î»µ½´óÄÔ£¬£¬£¬²¢ÔÚ²»ËðÉËÖÜΧ¿µ½¡×éÖ¯µÄÇéÐÎÏÂÓÐÓÃɱËÀÖ×Áö¡£¡£¡£¡£¡£ÕâÏîÍ»ÆÆÐÔÑо¿½ÒÏþÔÚ×î½üµÄ¡¶¿ÆÑ§¡·ÔÓÖ¾ÉÏ¡£¡£¡£¡£¡£
ÔĶÁ¸ü¶à
2024-12-25
Ö÷¹¥´óÄÔÑÛ¾¦ÌÇÄò²¡£¬£¬£¬È«Çò100¶àÏî¸Éϸ°ûÁÙ´²ÊÔÑéÕýÔÚ¾ÙÐÐ
µ¤Âó¸ç±¾¹þ¸ù´óѧµÄ¸Éϸ°ûÑо¿Ô±Agnete KirkebyºÍËýµÄͬÊÂÊÓ²ìÁËÈ«ÇòÔÙÉú¸Éϸ°ûÁÙ´²ÊÔÑéµÄÔ¶¾°¡£¡£¡£¡£¡£×èÖ¹2024Äê12Ô£¬£¬£¬ËûÃÇÈ·¶¨ÁË116ÏîÒÑÅú×¼»òÍê³ÉµÄÊÔÑ飬£¬£¬Ô¼ÄªÒ»°ëʹÓÃÈ˶àÄÜÅßÌ¥¸Éϸ°û×÷ΪÆðʼÖÊÁÏ£¬£¬£¬ÆäËûÑо¿Ê¹ÓÃÓÕµ¼¶àÐÑĿϸ°û¡£¡£¡£¡£¡£ÓÐ12ÏîÊÔÑéÊÔͼʹÓøÉϸ°ûȪԴµÄϸ°ûÀ´ÖÎÁÆÅÁ½ðÉ­²¡£¬£¬£¬ÓÐ29ÏîÊÔÑéÓÃÓÚÖÎÁÆÑÛ²¿¼²²¡£¬£¬£¬ÆäËû¼²²¡»¹°üÀ¨ÐÄÁ¦Ë¥½ß¡¢1ÐÍÌÇÄò²¡¡£¡£¡£¡£¡£
ÔĶÁ¸ü¶à
2024-12-18
ÍêÈ«»º½âÂÊÌá¸ß12%£¬£¬£¬×î¡°¶¾¡±ÈéÏÙ°©ÖÎÁÆÓÐÁË¡°Öйú¼Æ»®¡±
ÔÚ12ÔÂ10ÈÕ-13ÈÕ¾ÙÐеÄÈ«Çò×î´ó¹æÄ£ÈéÏÙ°©¾Û»á¡ª¡ª2024ÄêµÚ47½ìÊ¥°²¶«Äá°ÂÈéÏÙ°©×êÑлáÉÏ£¬£¬£¬¸´µ©´óѧÁ¥ÊôÖ×ÁöÒ½ÔºÉÛÖ¾Ãô½ÌÊÚÍŶÓÐû²¼µÄÒ»Ïî¸Ä±äÈýÒõÐÔÈéÏÙ°©Ð¸¨ÖúÖÎÁÆÄ£Ê½µÄÁÙ´²¢óÆÚÒªº¦Ñо¿Ð§¹û£¬£¬£¬³ÉΪ´ó»á¹Ø×¢ÈÈÃÅ¡£¡£¡£¡£¡£ÕâÏîÑо¿ÔÚͨÀýÝì»·¡¢×Ïɼ¡¢²¬Àà¡¢»·Á×õ£°·»¯ÁÆ»ù´¡ÉÏ£¬£¬£¬ÁªÓÃÖйúÔ­´´ÃâÒßÖÎÁÆÐÂÒ©¿¨ÈðÀûÖéµ¥¿¹£¨Ò»ÖÖPD-1µ¥¿Ë¡¿¹Ì壩£¬£¬£¬½«ÈýÒõÐÔÈéÏÙ°©Ð¸¨ÖúÖÎÁƵIJ¡ÀíѧÍêÈ«»º½âÂÊÌá¸ß12.1%£¨´Ó44.7%µ½56.8%£©£¬£¬£¬ÏÔÖøÓÅÓÚÄ¿½ñ³£ÓõϝÁƼƻ®¡£¡£¡£¡£¡£
ÔĶÁ¸ü¶à
2024-12-17
ÈÕ±¾Ñо¿Ö°Ô±·¢Ã÷Ò»ÖÖÖ¬·¾ËáÓÐÖúɱÃð°©Ï¸°û
ÈÕ±¾¶«±±´óѧÑо¿Ö°Ô±ÔÚÐÂÒ»ÆÚ¹ú¼ÊÆÚ¿¯¡¶Ï¸°ûéæÃüÓë¼²²¡¡·ÉϽÒÏþЧ¹û˵£¬£¬£¬Ò»Ð©Ê³ÎïÖк¬ÓеÄÒ»ÀàÃûΪ¹²éîÖ¬·¾ËáµÄÎïÖÊÄÜͨ¹ýÒý·¢Ï¸°û¡°ÌúéæÃü¡±À´É±Ãð°©Ï¸°û¡£¡£¡£¡£¡£ÕâÏîЧ¹ûÓÐÍû´øÀ´È«Ðµİ©Ö¢Ô¤·ÀºÍÖÎÁÆÒªÁì¡£¡£¡£¡£¡£
ÔĶÁ¸ü¶à
2024-12-12
ÐÂÎ÷À¼ÁܰÍÁö»¼ÕßÔÚ»¦½ÓÊÜCAR-TÁÆ·¨£¬£¬£¬ÏÖÔÚ²¡ÇéÍêÈ«»º½â
¿ËÈÕ£¬£¬£¬Ò»Î»À´×ÔÐÂÎ÷À¼µÄÁܰÍÁö»¼Õß´÷¶ûÏÈÉú½ÓÊܺ£ÄÚÒ½ÁÆ»ú¹¹ê×Ó°Ò½ÁÆÌṩµÄ¸öÐÔ»¯CAR-TÖÎÁƼƻ®£¬£¬£¬ÏÖÔÚÈ¡µÃÏÔÖøµÄÖÎÁÆÐ§¹û£¬£¬£¬¸´²éÆÀ¹ÀÏÔʾ¼²²¡ÍêÈ«»º½â£¬£¬£¬ÕâÒ»ÀÖ³ÉÖÎÁư¸Àý£¬£¬£¬ÔÙ´Î֤ʵÎúÖйúÔÚCAR-TÖÎÁÆÁìÓòµÄ¹ú¼Ê¾ºÕùÁ¦¡£¡£¡£¡£¡£
ÔĶÁ¸ü¶à
2024-12-06
±±´ó¹ú¼ÊҽԺѪҺÖ×Áö¼°Ï¸°ûÖÎÁÆÖÐÐĽ¨É裬£¬£¬¾Û½¹ÕïÁÆÐÂģʽºÍÐÂÇ÷ÊÆ
2024Äê12ÔÂ5ÈÕ£¬£¬£¬±±¾©´óѧ¹ú¼ÊÒ½Ôº¼´½«Ó­À´¿ªÕïÊ®ÖÜÄêµÄÀï³Ì±®Ê±¿Ì¡£¡£¡£¡£¡£±±¾©´óѧ¹ú¼ÊҽԺѪҺÖ×Áö¼°Ï¸°ûÖÎÁÆÖÐÐĵĽ¨ÉèÓëѧÊõ´ó»áµÄÕÙ¿ª£¬£¬£¬ÊÇÐÂµÄÆðµã£¬£¬£¬½«¿ªÆôÒ½ÔºÏÂÒ»¸öÊ®ÄêÉú³¤ºêͼ¡£¡£¡£¡£¡£Ò½ÔºÔÚÆ½°²¼¯ÍÅ¡¢±±¾©´óѧҽѧ²¿ºÍ±±´óÒ½ÁƼ¯ÍŵÄÏòµ¼Ï£¬£¬£¬Ò²½«Ò»Á¬¼ùÐС°°ì¹ú¼ÊÒ½Ôº£¬£¬£¬±ÙË¢ÐÂз¡±µÄÐÂʹÃü£¬£¬£¬¼á¶¨³¯×ÅÔ½·¢ÓÅÃÀµÄ¹ú¼Ê»¯Ò½ÁÆÊÂÒµÐÂÕ÷³ÌÀ«²½Ç°½ø¡£¡£¡£¡£¡£
ÔĶÁ¸ü¶à
2024-12-04
ÎÒ¹úѧÕß¿ª·¢¡°¶àϸ°ûÕÐµÄÃâÒßÖÎÁÆÐÂÕ½ÂÔ
ÔÚ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÏîÄ¿£¨Åú×¼ºÅ£º21432002¡¢21521003¡¢T2288102¡¢82150005¡¢32122035¡¢82274034£©×ÊÖúÏ£¬£¬£¬±±¾©´óѧ³ÂÅô½ÌÊÚÓ뱾Уϯ½¨ÖÒ½ÌÊÚ¡¢Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº¿µÏþÕ÷½ÌÊÚ¡¢ÄϾ©´óѧÀîÑÕ½ÌÊںͱ±¾©´óѧµÚÈýÒ½ÔºÁÖ¼áÑо¿Ô±ÏàÖú£¬£¬£¬¿ª·¢ÁËÒ»ÖÖ¡°¶àϸ°ûÕÐµÄÉúÎïÕý½»Ç¶ºÏÌ壬£¬£¬°ÐÏòʵÌåÁöÃâÒß΢ÇéÐΡ£¡£¡£¡£¡£Ïà¹ØÐ§¹ûÒÔ¡°¶àÌØÒìÐÔǶºÏÌåÓÃÓÚÖ×ÁöÃâÒß΢ÇéÐΰÐÏòµÄÕûºÏÃâÒßÁÆ·¨¡±£¨Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment£©ÎªÌ⣬£¬£¬ÓÚ2024Äê11ÔÂ5ÈÕÔÚ¡¶Ï¸°û¡·£¨Cell£©ÉϽÒÏþ¡£¡£¡£¡£¡£
ÔĶÁ¸ü¶à
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿